From 28–30 August 2026, MyRNA participated in GUT 2026, the Annual Scientific Meeting of the Malaysian Society of Gastroenterology & Hepatology (M...
From 28–30 August 2026, MyRNA participated in GUT 2026, the Annual Scientific Meeting of the Malaysian Society of Gastroenterology & Hepatology (MSGH), held in conjunction with the Endoscopy Workshop 2026 at the Kuala Lumpur Convention Centre (KLCC). The meeting, themed “Navigating the Changing Landscape of Digestive Diseases,” brought together gastroenterologists, hepatologists, surgeons, researchers, allied health professionals, and healthcare industry leaders to exchange knowledge and explore the latest developments in digestive disease management.
GUT 2026 provided an important platform for healthcare professionals to discuss emerging developments across gastroenterology and hepatology, including advancements in endoscopy, inflammatory bowel disease, hepatocellular carcinoma, obesity management, and other areas of digestive health. The event also featured a live endoscopy workshop, providing participants with opportunities to engage with leading endoscopists and gain insights into evolving clinical practices.
As a Malaysian molecular diagnostics company focused on advancing early cancer detection, MyRNA was proud to be part of this important scientific gathering. Through its exhibition booth, MyRNA introduced healthcare professionals to its GASTROClear™ blood-based molecular screening solution, which uses microRNA (miRNA) technology to support the risk stratification of gastric cancer.
The engagement provided an opportunity for MyRNA to share how innovative blood-based molecular screening may complement existing clinical approaches by helping identify individuals who may benefit from further clinical assessment. By providing a non-invasive and convenient screening option, GASTROClear™ represents MyRNA's commitment to exploring new approaches that can support earlier identification of individuals at increased risk of gastric cancer.
Throughout the three-day event, the MyRNA team engaged with gastroenterologists, hepatologists, surgeons, oncologists, healthcare professionals, and industry stakeholders, exchanging insights on the evolving landscape of cancer screening and the role of molecular diagnostics in preventive healthcare.The conversations at GUT 2026 also highlighted the importance of strengthening collaboration between diagnostic innovators and clinical communities. As gastric cancer continues to present challenges in detection and management, closer engagement with gastroenterology specialists is essential in understanding clinical needs and exploring pathways that can support earlier risk assessment and intervention. Beyond introducing GASTROClear™, MyRNA also used the event as an opportunity to strengthen relationships with healthcare professionals and explore potential collaborations that can expand access to innovative cancer screening technologies across Malaysia.
MyRNA extends its sincere appreciation to the Malaysian Society of Gastroenterology & Hepatology, the organising committee, speakers, delegates, and healthcare professionals who visited the MyRNA booth and engaged with the team throughout GUT 2026. The participation reflects MyRNA's continued commitment to working alongside the medical and scientific community to advance early cancer detection, preventive healthcare, and precision diagnostics. Through the continued development and adoption of innovative miRNA-based technologies, MyRNA aims to contribute to a future where cancer risk can be identified earlier and patients can be supported through more timely and informed clinical pathways.
